BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response.
J Heart Lung Transplant
; 40(8): 759-762, 2021 08.
Artículo
en Inglés
| MEDLINE | ID: covidwho-1198765
ABSTRACT
BACKGROUND:
Data on the safety and efficacy of SARS-CoV-2 vaccines in immunocompromised populations are sparse.METHODS:
We conducted a prospective study of 77 heart transplant (HT) recipients vaccinated with two doses of BNT162b2 vaccine and monitored for adverse events following both doses, the receptor-binding domain (RBD) IgG response, and neutralizing antibodies.RESULTS:
BNT162b2 vaccination was associated with a low rate of adverse events, characterized mostly by pain at the injection site. By a mean 41 days post second dose there were no clinical episodes of rejection, as suggested by a troponin leak or allograft dysfunction. At a mean 21 days following the second dose, IgG anti-RBD antibodies were detectable in 14 (18%) HT recipients. Immune sera neutralized SARS-CoV-2 pseudo-virus in 8 (57%) of those with IgG anti-RBD antibodies. Immunosuppressive regimen containing mycophenolic acid was associated with lower odds of an antibody response (ORâ¯=â¯0.12, pâ¯=â¯0.042).CONCLUSIONS:
Whether a longer time-frame for observation of an antibody response is required after vaccination in immunosuppressed individuals remains unknown.Palabras clave
Texto completo:
Disponible
Colección:
Bases de datos internacionales
Base de datos:
MEDLINE
Asunto principal:
Complicaciones Posoperatorias
/
Trasplante de Corazón
/
Vacunas contra la COVID-19
/
COVID-19
Tipo de estudio:
Estudio de cohorte
/
Estudio observacional
/
Estudio pronóstico
Tópicos:
Vacunas
Límite:
Anciano
/
Femenino
/
Humanos
/
Masculino
/
Middle aged
Idioma:
Inglés
Revista:
J Heart Lung Transplant
Asunto de la revista:
Cardiología
/
Trasplante
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS